Aug 2026· Endocrinology Research and Practice· 1 citation· 33 references
TL;DR
Overall, oral semaglutide appears to produce clinically meaningful reductions in body weight and BMI in adults without diabetes, while maintaining a safety profile consistent with other GLP-1 receptor agonists.
Abstract
Obesity is a major global health burden with limited long-term pharmacological options. Injectable semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown substantial weight loss, particularly in type 2 diabetes mellitus (T2DM). The efficacy of oral semaglutide in non-diabetic populations remains uncertain. To evaluate the efficacy and safety of oral semaglutide in adults without T2DM. A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 and Grade of Recommendation Assessment, Development and Evaluation guidance. MEDLINE, EMBASE, and Cochrane databases were searched. Randomized controlled trials (RCTs) comparing oral semaglutide with placebo in non-diabetic adults were included. Primary outcomes were changes in body weight and body mass index (BMI). Secondary outcomes included adverse events and serious adverse events. Five RCTs (n = 1096) with treatment durations of 10-68 weeks were included. Oral semaglutide significantly reduced body weight (mean difference (MD) −9.40 kg, 95% CI −13.53 to −5.27) and BMI (MD −3.27 kg/m2, 95% CI −5.00 to −1.53) compared with placebo. Although heterogeneity was high across studies (I2 > 90%), the direction of the effect was consistent, with all trials favoring oral semaglutide for weight-reduction outcomes. Adverse events were more frequent with oral semaglutide, particularly in the longer-duration trials, which showed a pooled odds ratio (OR) of 1.79 (95% CI 1.15-2.78). These events were predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation, consistent with the known safety profile of GLP-1 receptor agonists. Across all included studies, the overall adverse event estimate was also statistically significant (OR 1.93, 95% CI 1.30-2.86), indicating a higher likelihood of adverse events with oral semaglutide compared with placebo. However, serious adverse events were not increased (OR 0.97, 95% CI 0.60-1.55). Overall, oral semaglutide appears to produce clinically meaningful reductions in body weight and BMI in adults without diabetes, while maintaining a safety profile consistent with other GLP-1 receptor agonists.
Cite this article as: Garcia-Sierra AM, Cuya-Martínez JC, Giron F, Yepes-Núñez JJ. Efficacy and safety of oral semaglutide for weight loss in patients without diabetes: a systematic review and meta-analyses. Endocrinol Res Pract. Published online August 1, 2026. doi: 10.5152/ erp.2026.26919.
Liraglutide and semaglutide demonstrate significant superiority over placebo in reducing body weight and body mass index in obese children and adolescents and substantiate therapy in pediatric practice with careful assessment of the benefit-risk ratio.
E. A. Kovaleva, O. Nemyatykh, S. Okovity et al.· Medical Technologies. Assess...· 0 citations
BACKGROUND/OBJECTIVES
Obesity is a chronic, relapsing disease associated with multiple serious comorbidities. Semaglutide has emerged as an effective pharmacological option for obesity management, owing to its substantial effects on weight loss, cardiometabolic risk factors, and patient-reported outcomes. This systemat...
Agostino Milluzzo, V. Oteri, Lucia Manuella et al.· International Journal of Obe...· 0 citations
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in obesity and type 2 diabetes mellitus (T2DM), but comparative real-world evidence from the Middle East remains limited. We compared the effectiveness, documented adverse events, adherence and persistence of once-weekly semaglutide and o...
Najwa Al Himali, Hanan Al Habsi, Ahmed Al Mushrafi et al.· Journal of Clinical Medicine· 0 citations
Background: The systematic review was done with an objective to assess efficacy and safety of anti-obesity medications (AOMs), FDA-approved and emerging, in various populations (older than 50 years of age, children, and individuals with type 2 diabetes [T2DM]); and to analyze cardiometabolic outcomes. Material and Meth...
K. Ram, Syed Haris Bukhari, Rahul Arora et al.· Acta Medica International· 0 citations
Introduction: Semaglutide has shown substantial weight reduction in trials, but real-world evidence from South Asian populations is scarce. We evaluated the efficacy and safety of once-weekly semaglutide 2·4 mg over 26 weeks in adults with overweight or obesity, with and without type 2 diabetes mellitus (T2DM).
Methods...
Q. T. Islam· Journal of Association of Cl...· 0 citations
Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agoni...
Ahmad Hassan, Qurrat Ul Ain Farooq, Fnu Parwesh et al.· F1000Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.